目的 观察玄七健骨片联合艾瑞昔布片治疗轻中度膝骨关节炎（筋脉瘀滞证）的应用效果。方法 纳入山西省汾阳医院2024年1～12月收治的轻中度膝骨关节炎（筋脉瘀滞证）患者64例，所有患者按照随机数字表法分为对照组和治疗组，各32例。对照组饭后口服艾瑞昔布片，1片/次，2次/d。治疗组在对照组的基础上口服玄七健骨片，4片/次，3次/d。两组均治疗8周。对比两组的临床疗效、临床症状、膝关节功能、血清炎症因子。结果 治疗组的总有效率为96.88%，高于对照组的总有效率78.13%（P＜0.05）。两组治疗后西安大略和麦克马斯特大学骨关节炎指数（WOMAC）、视觉模拟评分法（VAS）评分下降，关节炎生活质量测量量表2-短卷（AIMS2-SF）评分升高（P＜0.05）；治疗组治疗后WOMAC、VAS评分低于对照组，AIMS2-SF评分高于对照组（P＜0.05）。两组治疗后美国特种外科医院（HSS）膝关节评分、膝关节活动度升高（P＜0.05）；治疗组治疗后HSS膝关节评分、膝关节活动度高于对照组（P＜0.05）。两组治疗后血清白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、C反应蛋白（CRP）水平均下降（P＜0.05），治疗组的血清IL-1β、IL-6、CRP水平低于对照组（P＜0.05）。结论 玄七健骨片联合艾瑞昔布片治疗轻中度膝骨关节炎（筋脉瘀滞证）可有效改善临床症状和膝关节功能，降低炎症因子水平。

Objective To observe the application effect of Xuanqi Jiangu Tablets combined with Imrecoxib Tablets in treatment of mild to moderate knee osteoarthritis (muscle and vein stasis syndrome). Methods 64 Patients with mild to moderate knee osteoarthritis (muscle stasis syndrome) admitted to Shanxi Fenyang Hospital from January to December 2024 were included. All patients were divided into control group and treatment group using a random number table method, with 32 patients in each group. The control group took orally Imrecoxib Tablets after meals, 1 tablets/time, twice daily. The treatment group took orally Xuanqi Jiangu Tablets on the basis of the control group, 4 tablets/time, 3 times daily. Patients in two groups were treated for 8 weeks. The clinical efficacy, clinical symptoms, knee joint function, and serum inflammatory factors were compared between patients in two groups. Results The total effective rate of the treatment group was 96.88%, which was higher than the total effective rate of 78.13% in the control group (P < 0.05). After treatment, Western Ontario and McMaster University Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) scores in two groups decreased, but the Arthritis Quality of Life Scale 2-Short Form (AIMS2-SF) scores increased (P < 0.05). After treatment, the WOMAC and VAS scores of the treatment group were lower than those of the control group, but the AIMS2-SF score was higher than that of the control group (P < 0.05). After treatment, the Hospital for Special Surgery (HSS) knee joint score and knee joint range of motion in two groups increased (P < 0.05). After treatment, the HSS knee joint score and knee joint range of motion in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and C-reactive protein (CRP) in two groups decreased (P < 0.05), and the serum levels of IL-1β, IL-6, and CRP in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Xuanqi Jiangu Tablets and Imrecoxib Tablets in treatment of mild to moderate knee osteoarthritis (muscle and vein stasis syndrome) can effectively improve clinical symptoms and knee joint function, and reduce levels of inflammatory factors.

R982

吕梁市重点研发项目（2020SHFZ64）